Bathi sadurunge mbayar bunga, pajak, lan amortisasi: sanofi.com (SNY)

Logo grafis sanofi.com (SNY)

The French behemoth Sanofi (SNY) relies on high-demand vaccines and treatments for chronic pathologies, while the success of Dupixent guarantees a highly reliable cash flow. EBITDA_Co monitoring confirms this resilience, where 22337.53 represents the current metric value. An impeccable image as a classic manufacturer and a positive business restructuring maintain a high level of trust from the global medical community.

Sanofi (SNY) - Bathi operasional EBITDA saka 23.11.2025 nganti 10.11.2026

Sanofi S.A. (SNY) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Rega bursa Sanofi Group|SNY - Bagan rega target
- indikator kapitalisasi bursa perusahaan:
Nilai pasar Sanofi|SNY - Nilai Perusahaan
- rincian valuasi buku bisnis:
Ekuitas saben Saham Sanofi|SNY - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku sanofi.com|SNY - Aset Agregat Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Rasio Utang marang Ekuitas Sanofi|SNY - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Sanofi SA|SNY - Utang perusahaan|Utang-utang marang aset resik Sanofi|SNY - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Sanofi|Rasio likuiditas darurat sanofi.com
- indikator bathi lan kelipatan valuasi:
SNY - Bathi resik perusahaan|Bathi resik sing dikarepake Sanofi|SNY - Pangali P/E|Rasio rega marang bathi sing dikarepake sanofi.com|SNY - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Sanofi|SNY - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Sanofi|SNY - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan sanofi.com|SNY - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham ing taun ngarep Sanofi
Analisis kabeh metrik perusahaan:SNY Sanofi Group
Barang unggulan Sanofi S.A.

This metric measures the actual cash flow from core operations before deducting depreciation and interest. It reflects the business's ability to generate liquidity to cover operating expenses amid inflation. Analyzing actual EBITDA allows for the identification of hidden margin compression resulting from rising costs. For Sanofi (SNY), this metric confirms the defensive qualities of the business. Stable revenue from immunology drugs ensures capital resilience during the company's restructuring.

Karo sapa Sanofi saingan

Eli Lilly and Co. (LLY) - Bathi sadurunge bunga, pajak, lan amortisasi|ABBV - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|AZN: Bathi sadurunge mbayar bunga, pajak, lan amortisasi|NVS: Bathi operasional EBITDA|Bathi operasional sadurunge amortisasi MRK|NVO (Novo Nordisk Inc.) - Bathi operasional EBITDA|Amgen Inc (AMGN) - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Pfizer Inc. (PFE)|bms.com - Bathi operasional sadurunge amortisasi|Bathi operasional EBITDA GSK (GlaxoSmithKline)|Bathi operasional sadurunge potongan amortisasi Takeda Pharmaceutical Company|TEVA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi Dr. Reddy's Labs RDY|VTRS: Bathi operasional EBITDA|roivant.com (ROIV) - Bathi operasional EBITDA|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Zai Lab|Bathi operasional sadurunge amortisasi BHC (Bausch Health Companies Inc.)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Cosmos Holdings (COSM)